FindTrial
Sign In

Preliminary study on the difference of VHL expression intensity between primary tumor mass and metastatic tumor mass of advanced/metastatic renal clear cell carcinoma

Preliminary study on the difference of VHL expression intensity between primary tumor mass and metastatic tumor mass of advanced/metastatic renal clear cell carcinoma

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2200059890
Enrollment
Unknown
Registered
2022-05-13
Start date
2022-05-16
Completion date
Unknown
Last updated
2024-04-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Renal cancer

Interventions

Advanced/metastatic renal clear cell carcinoma:None

Sponsors

Tongji Hospital, Tongji Medical College of Huazhong University of Science and Technology
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Renal clear cell carcinoma diagnosed by pathology; 2. Patients considered as advanced/metastatic clear cell renal carcinoma by imaging examination including PET-CT, CT or MRI: T4N0-1m0/T1-4n0-1m1; 3. Primary and metastatic tissues of renal cell carcinoma can be obtained.

Exclusion criteria

Exclusion criteria: 1. Patients with other neoplastic diseases; 2. Renal cell carcinoma with other pathological types other than renal clear cell carcinoma.

Design outcomes

Primary

MeasureTime frame
Expression intensity of VHL protein;Expression intensity of CAXI protein;—

Countries

China

Contacts

Public ContactHeng Li

Tongji Hospital, Tongji Medical College of Huazhong University of Science and Technology

lihengtjmu@163.com+86 18986292538

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026